At present, a large number of recombinant viruses are being assessed in cancer gene therapy protocols, including adenovirus and parvovirus-based vectors. Autonomous parvoviruses are small non-enveloped nuclearreplicating viruses containing a single-stranded DNA genome with palindromic hairpin ends.
At present, a large number of recombinant viruses are being assessed in cancer gene therapy protocols, including adenovirus and parvovirus-based vectors. Autonomous parvoviruses are small non-enveloped nuclearreplicating viruses containing a single-stranded DNA genome with palindromic hairpin ends. 1 The prototype parvovirus minute virus of mice (MVM) and the closely related virus H-1, have been shown to preferentially replicate and exert cytopathic effects in various oncogenetransformed cells while sparing their non-transformed counterparts in vitro and in vivo. 2 Hence, MVM and H-1 virus-based vectors have been constructed for cancer gene therapy purposes, which retain in particular the oncogene-responsive parvoviral expression cassette, including the gene coding for the multifunctional (replicative, transactivating and cytotoxic) nonstructural protein 1 (NS1). 3 Parvoviral vectors proved to be endowed with the capacity of parental viruses for targeting transformed cells on the level of gene expression, 4 yet their use is limited by the relative inefficiency of the systems for vector production available to date. Adenovirus vectors, in contrast, lack the oncotropism of parvovirus vectors, but can be produced in very large amounts. We therefore tried to combine the advantages of both vectors in chimeric adenovirus vectors that carry the parvoviral expression cassette and should be amenable to the high titer production of recombinant adenoviruses. The investigation, however, had to face a major difficulty, namely the complete suppression of recombinant adenoviruses production as a result of the presence of the parvoviral NS gene. The present report shows that this problem can be overcome by transfecting the packaging cells with antisense oligonucleotides targeting specific sequences of NS transcripts.
To construct adeno-parvovirus chimeras, two sequences from the H-1 parvoviral genome were inserted into a first generation adenovirus 5-based vector. Both inserts direct expression of the LacZ transgene under the control of the strong cell-cycle and oncogene-inducible 5 parvoviral promoter P4, either directly ( Figure 1a , pAd-P4-lacZ) or through the transactivation of the parvovirus P38 promoter by the parvoviral NS1 protein (Figure 1a , pAd-P4-NS-P38-lacZ). In the latter construct, the NS gene was included to endow the chimeric viruses with NS1-dependent capacity both for preferential toxicity and activation of therapeutic transgene expression in tumor cells. After transfection of the Ad-P4-lacZ construct into 293 or 293T complementation cells, recombinant virus was obtained. In contrast, the Ad-P4-NS-P38-lacZ construct failed to yield detectable amounts of recombinant adenoviruses after transfection into either type of packaging cells (see below). This lack of adenovirus production can in all probability be assigned to the vector-driven expression of the parvoviral NS1 protein in the transfected cells. Indeed, it has been shown previously that the NS1 protein is cytotoxic and interferes with a number of intracellular processes. 3, 8, 9 These observations led us to reason that production of adeno-parvoviruses may be achieved by inhibiting temporarily NS1 expression in packaging cells. Antisense strategies have been successfully applied to inhibit infections with various viruses, including parvovirus MVM. 10 The state-of-the-art points to synthetic modified oligodeoxyribonucleotides as especially practical, stable and efficient antisense effectors. 11 This prompted us to determine whether this antisense technology could be applied to transiently protect producer cells from the effects of a toxic gene (NS1) after transfection of the recombinant adenoviral vector genome into packaging cells. To this end several antisense phosphorothioate oligonucleotides (PS) were designed for targeting the translation initiation region of the NS transcript ( Figure 1b) . The phosphorothioate modification (replacing one of the nonbridging oxygens by sulfur) prevents DNase cleavage of the oligonucleotides, while preserving the susceptibility of their DNA:RNA duplexes to RNaseH digestion. 12 The maximum amounts of PS oligos that could be administered to 293T cells by calcium phosphate transfection without causing detectable toxicity were determined to lie in the range of 5-10 g per 1.8 × 10 6 cells. In these quantities, PS oligos were first tested for their ability to Gene Therapy (Figure 2a, lanes 1-7) revealed that antisense PS2, PS3 and PS4 had inhibitory effects, with PS3 being most efficient in suppression of intracellular NS1 accumulation. In contrast, neither the equivalent of PS3 in sense orientation (PS3sense) nor the PS5 control (unrelated sequence) showed inhibitory activity. These data were further confirmed by cotransfecting cells with the reporter plasmid P4-NS-P38-EGFP and the respective PS oligos. Thus, EGFP expression served as an indicator of the amount of NS1 protein available to transactivate the P38 promoter. The results (Figure 2b) showed that the cotransfection of PS oligos which target the NS1 gene, reduced EGFP gene expression from the P38 promoter. The most effective inhibition was again observed with PS3. Thus, the strong suppression of NS1 expression with PS3 should allow minimization of the toxicity due not only to NS protein, but also to the products of deleterious transgenes placed under control of promoter P38. In order to check that the antisense oligonucleotides indeed controlled the NS1 gene expression at the mRNA level, RT-PCR analysis was performed. We analyzed total cellular RNA from 293T cells cotransfected with pSR19 and PS3 or PS5, respectively. As illustrated in Figure 2c , the level of NS1 transcripts was drastically reduced in the presence of PS3, while the PS5 negative control had no effect. This suppression was specific for the NS1 mRNA, in keeping with the expected ability of antisense oligonucleotides to mediate degradation of the transcripts to which they are complementary. These results led us to finally verify the capacity of antisense PS3 for silencing NS1 gene expression in a cotransfection of the oligo with the chimeric adeno-parvoviral DNA clone pAd-P4-NS-P38-lacZ. As shown in Figure 2a (lanes 8 and 9) , PS3 indeed strongly reduced NS1 protein accumulation in the transfected 293T cells. This efficient suppression of NS1 from adenoviral vector DNA, using PS3 oligo, raised hopes of achieving the production of recombinant adenoviruses harboring the parvoviral P4-NS-P38 expression cassette in 293 complementation cell lines.
Figure 2 Antisense PS oligo-induced inhibition of NS1 expression. (a) Western blotting analysis of NS1 expression in cells transfected with NS1 expressing plasmids in the presence or absence of PS oligos. The plasmids used were pSR19 (an infectious H-1 virus DNA clone) and pAd-P4-NS-P38-lacZ (a chimeric adeno-parvovirus DNA clone
Recombinant adenovirus particle production was measured in the 293T complementation cell line for the two chimeras depicted in Figure 1a . Cells transfected with either DNA clone were harvested by scraping at day 6 or 7 after the initial transfection, and lysed through two freeze/thaw cycles. Supernatants were clarified by centrifugation, and used to infect 293T cells in order to titer and further amplify the burst of recombinant adenoviruses recovered from transfected cells. At the end of this infection step, viruses were collected and titered again. To determine the yields of recombinant adenovirus production, serial dilutions of cell supernatants were applied to 293T indicator cells, and virus titers were determined by infected cell hybridisation assays, using a 32 P-labelled specific DNA probe, or by counting of ␤Gal-expressing (blue) cells after X-gal staining. The results obtained are summarized in Table 1 . Transfection of the Ad-P4-lacZ DNA clone into 293T cells (protocol B) led to the production of recombinant adenovirus particles that were competent for replication and LacZ transduction upon infection of indicator cells. The Ad-P4-lacZ virus stock collected from transfected cells became amplified during this round of infection in 293T cells. In contrast, mock-transfected cultures did not release recombinant virus particles (protocol A). Transfection of the Ad-P4-NS-P38-lacZ construct into 293T cells did not result in the production of detectable infectious virus (protocol C), unless cultures were cotransfected with PS3 (protocols D and E). This was apparent from the measurement of the capacities of transfected cell extracts for both viral DNA transfer and LacZ transduction (Figure 3) . Furthermore, the chimeric adenoviruses recovered from Ad-P4-NS-P38-lacZ DNA plus PS3 cotransfected cells, were able to multiply in 293T cultures following infection, provided that the cells were concomitantly treated with PS3 (compare protocols D and E in Table 1 ). It is concluded from these data that the NS insert impairs the growth of hybrid adenoviruses and that the antisense PS strategy can be successfully applied to overcome this inhibition, allowing both the initial generation of Ad-P4-NS-P38-lacZ viral vectors from transfected DNA, and the further amplification of these viruses through a successive round of infection. It should be stated that the PS transfection procedure did not impair in any way the concomitant infection of cells with recombinant adenoviruses, as ascertained in conditions in which the PS treatment was not required for a productive adenovirus infection (P4-lacZ construct). It is also worth noting that the titers of the Ad-P4-NS-P38-lacZ virus stocks obtained in the presence of PS3 were about 25-fold lower than those of the Ad-P4-lacZ vector devoid of NS gene. Thus, the PS3-induced reduction of NS1 mRNA in Ad-P4-NS-P38-lacZtransfected cells was enough to release adenovirus production from the NS block, but the residual NS1 expression resulted in suboptimal virus yields. However, the vector titer obtained in our experiments is clearly high enough to envisage the use of such recombinant, therapeutic gene-containing vectors in gene transfer protocols.
The negative interference of the NS1 gene with hybrid adenovirus production is in keeping with the previously reported ability of parvovirus H-1 to inhibit cell coinfection with adenovirus 12.
15 Furthermore, the Rep 78 protein of the adeno-associated viruses (another genus of the Parvoviridae family), which shares many properties with NS1, proved capable of impairing the maturation of adenovirus replication centers. 16 H-1 virus NS1 can be assumed to induce similar cellular disturbances which impede adenovirus replication. Overcoming this problem is clearly a prerequisite for gene therapy applications using adeno-parvoviral hybrid vectors. Yet, this incompatibility between vector production and transgene expression is not unique to the present system, since a number of transgenes, encoding in particularly toxins, were found to significantly decrease the yield of recombinant vector production. 17 This problem may be circumvented by placing the transgene under control of an inducible or tissue-specific promoter which is switched off in the packaging cells during the vector production phase. However, such promoters are often rather weak, and most importantly, many of them are leaky and do not allow for efficient vector production. It is thus important to devise alternative strategies to transiently silence these transgenes during the process of viral vector production. As exemplified by this study, the antisense PS methodology can be successfully applied to this end. It allowed the expression of the potent parvoviral NS1 toxin to be reduced to an extent that was compatible with the production of recombinant adenoviruses. Given that short synthetic oligonucleotides specific for other problematic transgenes can be easily made and tested, this approach is likely to be of general utility in a variety of recombinant vector production systems. Thus, the antisense PS strategy could be applicable to the packaging of any virus engineered to express a toxic gene product. In the present work, antisense PS were administered through calcium phosphate transfection into the easily a Adenovirus vectors were produced in 293T cultures (1.8 × 10 6 cells/10 cm petri dish), using a two-step procedure. In step 1, plasmid DNA was linearised with PacI digestion 14 and transfected (15 g of the indicated constructs/plate) or not (mock) into 293T cells, using the calcium phosphate coprecipitation method. In step 2, the virus produced by transfected cells was harvested and used to infect new cultures. At the time of vector (DNA or viurs) transfection or infection, cultures were concomitantly transfected (+PS3) or not (ϪPS3) with the antisense olignonuceotide (8 g/plate) according to the calcium phosphate procedure. During the transfection step period, the PS3 treatment was repeated twice, at 2-3 day intervals.
b At the end of each step the viruses in cellular extracts were titered by infecting 293T indicator cultures and determining the numbers of cells positive for viral DNA replication or ␤-Gal expression by cell hybridization and X-gal staining, respectively (see Figure 3) . Corresponding titers are expressed as replication units (RU) and transduction units (TU). Indicated values are total titers from 9 × 10 5 initially transfected cells in a typical experiment. Similar results were obtained in three independent experiments. BD, below detection (less than 10 2 units per extract). transfectable 293T complementation cells. We further showed that PS transfection can be performed concomitant with adenoviral vector infection, allowing further amplification of the primary recombinant virus stocks. Although PS oligos can enter the cells in the absence of any treatment, the uptake efficiency was increased manyGene Therapy fold by the transfection procedure, as measured by FACS analysis using a FITC-labelled PS oligo (data not shown). Other ways of PS administration can be applied to complementation cells for which the calcium phosphate method is not suitable, such as liposomes which have proven to be efficient carriers for the delivery of oligonucleotides. A practical limitation to the PS antisense approach lies in scaling up, ie the high amounts of oligonucleotides needed to produce large quantities of vectors. In order to overcome this restriction, the PS strategy may be combined with the above-mentioned use of conditional promoters to silence transgene expression at both transcriptional and post-transcriptional levels. Given the dose dependence of PS activity, reduced amounts of PS oligonucleotides may be sufficient to provide the required protection under these conditions. An alternative approach would consist of expressing non-modified, but still effective, antisense products from a transcription unit that has been stably incorporated into the packaging cell line, assuming that an adequate level and persistence of expression can be achieved. Antisense oligonucleotides therefore appear to be powerful and versatile tools to protect complementation systems against gene products whose expression is harmful to or interferes with the production of viral vectors.
Figure 3 Titration of recombinant adenoviruses produced after cell transfection with pAd-P4-NS-P38-lacZ plus or minus PS3. The experimental scheme is depicted in

